TanWAboulhosnJ. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol. 2020; 309:70–7.
2.
BaltaSMikhailidisDPDemirkolSOzturkCKurtogluEDemirM, et al.Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773–7.
3.
IcliACureECureMCUsluAUBaltaSMikhailidisDP, et al.Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Angiology. 2016;67:749–55.
4.
MedetalibeyogluAEmetSKoseM, et al.Serum endocan levels on admission are associated with worse clinical outcomes in COVID-19 patients: a pilot study. Angiology. 2020; in press.
5.
BaltaSMikhailidisDPDemirkolSOzturkCCelikTIyisoyA. Endocan: A novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243(1):339–43.
6.
CelıkTBaltaSKaramanMAhmet AySDemırkolSOzturkC, et al.Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: Comparative effects of amlodipine and valsartan. Blood Press. 2015;24:55–60.
7.
BaltaIBaltaSKoryurekOMDemirkolSMikhailidisDPCelikT, et al.Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70:291–6.
8.
BaltaIBaltaSDemirkolSMikhailidisDPCelikTAkhanM, et al.Elevated serum levels of endocan in patients with psoriasis vulgaris: Correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169:1066–70.
9.
YilmazMISiriopolDSaglamMKurtYGUnalHUEyiletenT, et al.Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86:1213–20.
